Eculizumab: Difference between revisions
Jump to navigation
Jump to search
m (Protected "Eculizumab": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
| Line 29: | Line 29: | ||
==References== | ==References== | ||
{{reflist|2}} | |||
==External links== | ==External links== | ||
Revision as of 17:02, 4 September 2012
Template:Drugbox-mab Eculizumab (rINN and USAN, trade name Soliris) is a monoclonal antibody directed against the complement protein C5. This antibody blocks the cleavage of C5 and halts the process of complement-mediated cell destruction. Eculizumab is a product of Alexion Pharmaceuticals and has been shown to be effective in treating paroxysmal nocturnal hemoglobinuria.[1] Eculizumab was approved by the United States Food and Drug Administration (FDA) on March 16, 2007.
References
- ↑ Hillmen P, Young N, Schubert J, Brodsky R, Socié G, Muus P, Röth A, Szer J, Elebute M, Nakamura R, Browne P, Risitano A, Hill A, Schrezenmeier H, Fu C, Maciejewski J, Rollins S, Mojcik C, Rother R, Luzzatto L (2006). "The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria". N Engl J Med. 355 (12): 1233–43. PMID 16990386.